Vita 34 AG
Vita 34 AG (V3V.DE) Stock Overview
Explore Vita 34 AG’s financial performance, market position, analyst ratings, and future outlook.
V3V.DE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Vita 34 AG (V3V.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $3.67.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 28.22 and a market capitalization of 72.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Jakub Julian Baran
783
Deutscher Platz 5a, Leipzig
2007